Determination of In Vitro Cytochrome P450 Induction Potential Using Cryopreserved Human Hepatocytes

Author(s):  
Susan Wong
2008 ◽  
Vol 36 (6) ◽  
pp. 1046-1055 ◽  
Author(s):  
Niresh Hariparsad ◽  
Brian A. Carr ◽  
Raymond Evers ◽  
Xiaoyan Chu

2006 ◽  
Vol 35 (2) ◽  
pp. 215-220 ◽  
Author(s):  
Georgina Meneses-Lorente ◽  
Christine Pattison ◽  
Claire Guyomard ◽  
Christophe Chesné ◽  
Robert Heavens ◽  
...  

Author(s):  
MARTHA GARCIA ◽  
JOSEPH RAGER ◽  
QING WANG ◽  
ROBERT STRAB ◽  
ISMAEL J. HIDALGO ◽  
...  

Author(s):  
María José Gómez-Lechón ◽  
Agustín Lahoz ◽  
José V. Castell ◽  
María Teresa Donato

Molecules ◽  
2019 ◽  
Vol 24 (4) ◽  
pp. 818
Author(s):  
Ju-Hyun Kim ◽  
Sunjoo Kim ◽  
Jaesin Lee ◽  
Sangwhan In ◽  
Yong-Yeon Cho ◽  
...  

25B-NBF, 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-fluorobenzyl)ethanamine, is a new psychoactive substance classified as a phenethylamine. It is a potent agonist of the 5-hydroxytryptamine receptor, but little is known about its metabolism and elimination properties since it was discovered. To aid 25B-NBF abuse screening, the metabolic characteristics of 25B-NBF were investigated in human hepatocytes and human cDNA-expressed cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes using liquid chromatography–high resolution mass spectrometry. At a hepatic extraction ratio of 0.80, 25B-NBF was extensively metabolized into 33 metabolites via hydroxylation, O-demethylation, bis-O-demethylation, N-debenzylation, glucuronidation, sulfation, and acetylation after incubation with pooled human hepatocytes. The metabolism of 25B-NBF was catalyzed by CYP1A1, CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2J2, CYP3A4, and UGT2B7 enzymes. Based on these results, it is necessary to develop a bioanalytical method for the determination of not only 25B-NBF but also its metabolites in biological samples for the screening of 25B-NBF abuse.


2012 ◽  
Vol 18 (2) ◽  
pp. 199-210 ◽  
Author(s):  
Robert D. Pelletier ◽  
W. George Lai ◽  
Y. Nancy Wong

Induction of the cytochrome P450 (CYP) family of enzymes by coadministered compounds can result in drug-drug interactions, as in the case of the coadministration of rifampicin with many CYP3A substrates, including midazolam. Identification of potential drug-drug interactions due to CYP induction during drug discovery is critical. We present a substrate cocktail method that was applied to assess the induction of CYP1A, CYP2B6, CYP2C9, and CYP3A using a 96-well high-throughput format. Viable cell counts were determined using a high-content screening system to normalize activities. Substrate cocktail incubations demonstrated a similar fold induction for known inducers as compared with discrete probe incubations. The system was further validated by determining the induction potency of rifampicin. The Emax and EC50 values in two separate lots of hepatocytes for CYP3A induction by rifampicin in a 96-well format were similar when discrete probe was compared with the probe cocktail. This system has been demonstrated to be suitable for high-throughput assessments of CYP induction.


2004 ◽  
Vol 67 (3) ◽  
pp. 427-437 ◽  
Author(s):  
Dirk Roymans ◽  
Cis Van Looveren ◽  
Angelique Leone ◽  
J.Brandon Parker ◽  
Michael McMillian ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document